<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57161">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02092233</url>
  </required_header>
  <id_info>
    <org_study_id>LMA-HSV-01-CS-001</org_study_id>
    <nct_id>NCT02092233</nct_id>
  </id_info>
  <brief_title>A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&amp;2 Assay in Symptomatic Patients</brief_title>
  <official_title>A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&amp;2 Assay in Symptomatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luminex Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luminex Molecular Diagnostics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ARIES HSV 1&amp;2 Assay is a PCR based test for the direct detection and typing of herpes
      simplex virus (HSV 1 &amp; 2) DNA.

      The objective is to establish the diagnostic accuracy of ARIES HSV-1&amp;2 Assay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ARIES HSV 1&amp;2 Assay is a polymerase chain reaction (PCR) based qualitative in vitro
      diagnostic test for the direct detection and typing of herpes simplex virus (HSV 1 &amp; 2) DNA
      in male external and internal anogenital, female external and internal anogenital (vaginal),
      oral and skin lesion specimens.

      The objective is to establish the diagnostic accuracy of ARIES HSV-1&amp;2 Assay through a
      multi-site, method comparison on prospectively collected, left-over de-identified, clinical
      specimens (i.e. all-comers accrued at enrolled clinical sites between pre-determined dates)
      as an aid in the diagnosis of herpes infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Diagnostic accuracy will be expressed in terms of clinical sensitivity (or positive agreement) and specificity (or negative agreement).</measure>
    <time_frame>Within the first year of sample collection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Herpes</condition>
  <arm_group>
    <arm_group_label>Blinded, Prospective Arm</arm_group_label>
    <description>The diagnostic accuracy for lesions from individuals suspected of having a herpes infection will be evaluated in prospectively collected, left-over de-identified, clinical specimens accrued between pre-defined dates.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded, Pre-selected Arm</arm_group_label>
    <description>For specimen types that are less common, banked, pre-selected, positive clinical specimens will be tested.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patient lesion swab specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Clinical lesions from pediatic or adult patients suspected of having herpes infection
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The specimen is from one of the following lesion sources: male internal and external
        anogenital, female internal anogenital, female external anogenital, oral or skin The
        specimen is collected and maintained in unexpired Copan universal transport medium

        Exclusion Criteria:

        The specimen was not properly collected, transported or stored according to instructions
        provided by Sponsor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Himsworth</last_name>
    <role>Study Director</role>
    <affiliation>Luminex Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ian Ridd, Ph.D</last_name>
    <email>iridd@luminexcorp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Lebel</last_name>
      <phone>413-322-4701</phone>
      <email>kimberly.lebel@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Franklin Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tricore</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Kindig</last_name>
      <phone>505-938-8126</phone>
      <email>sandra.kindig@tricore.org</email>
    </contact>
    <investigator>
      <last_name>Steven Young, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Labcorp</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hunt</last_name>
      <phone>336-436-3869</phone>
      <email>huntm@labcorp.com</email>
    </contact>
    <investigator>
      <last_name>Barbara Body, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARIES HSV 1&amp;2</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
